August 29, 2024 07:17 AM EDT
People
R&D

Pre­clin­i­cal team hit hard­est in Re­pare's R&D pri­or­i­ti­za­tion, lay­offs

Katherine Lewin

News Reporter

Re­pare Ther­a­peu­tics is cut­ting its head­count by about 25%, with most of the lay­offs con­cen­trat­ed in the com­pa­ny’s pre­clin­i­cal team, as part of what the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck fi­nal­ly has sub­cu­ta­neous Keytru­da re­sults, and it's go­ing to reg­u­la­tors

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

In­cyte’s bet on Escient hits a snag as safe­ty is­sues ham­per Phase 2 chron­ic hives tri­al

FDA of­fers more guid­ance on de­vel­op­ing cell and gene ther­a­pies

Rock­et shares promis­ing long-term re­sults from rare heart dis­ease gene ther­a­py in small study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times